Genomics & Resistant Microbes (GeRM) Group, Facultad de Medicina Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.
Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
J Clin Microbiol. 2022 Sep 21;60(9):e0084321. doi: 10.1128/jcm.00843-21. Epub 2022 Jun 13.
Enterococci are major, recalcitrant nosocomial pathogens with a wide repertoire of intrinsic and acquired resistance determinants and the potential of developing resistance to all clinically available antimicrobials. As such, multidrug-resistant enterococci are considered a serious public health threat. Due to limited treatment options and rapid emergence of resistance to all novel agents, the clinical microbiology laboratory plays a critical role in deploying accurate, reproducible, and feasible antimicrobial susceptibility testing methods to guide appropriate treatment of patients with deep-seated enterococcal infections. In this review, we provide an overview of the advantages and disadvantages of existing manual and automated methods that test susceptibility of Enterococcus faecium and Enterococcus faecalis to β-lactams, aminoglycosides, vancomycin, lipoglycopeptides, oxazolidinones, novel tetracycline-derivatives, and daptomycin. We also identify unique problems and gaps with the performance and clinical utility of antimicrobial susceptibility testing for enterococci, provide recommendations for clinical laboratories to circumvent select problems, and address potential future innovations that can bridge major gaps in susceptibility testing.
肠球菌是主要的、顽固的医院病原体,具有广泛的内在和获得性耐药决定因素,并有发展为对所有临床可用的抗菌药物的耐药性的潜力。因此,多药耐药肠球菌被认为是严重的公共卫生威胁。由于治疗选择有限,以及对所有新型药物的耐药性迅速出现,临床微生物学实验室在部署准确、可重复和可行的抗菌药物敏感性测试方法方面发挥着关键作用,以指导对深部肠球菌感染患者的适当治疗。在这篇综述中,我们概述了现有的手动和自动化方法在测试粪肠球菌和屎肠球菌对β-内酰胺类、氨基糖苷类、万古霉素、脂糖肽类、恶唑烷酮类、新型四环素衍生物和达托霉素的敏感性方面的优缺点。我们还确定了肠球菌抗菌药物敏感性测试的性能和临床实用性方面存在的独特问题和差距,为临床实验室提供了规避特定问题的建议,并探讨了可能的未来创新,可以弥合敏感性测试中的主要差距。